Two more PD-(L)1 combination trials which accept MSS-CRC patients that a friend brought my attention to:
1.) A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers NCT02327078 https://clinicaltrials.gov/ct2/show/NCT02327078 Multiple sites nation-wide. Adds in an “IDO1 inhibitor” to remove immunosuppression signals from the tumor.
2.) MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors NCT02503774 https://www.clinicaltrials.gov/ct2/show/NCT02503774 I know of at least one more site on the east coast not listed on the clinicaltrials.gov page so call for current locations. Adds in MEDI9447 an “ant-CD73” drug to remove immunosuppression signals from the tumor.
You can see the continuing general strategy to expand PD-(L)1 inhibition to MSS-CRC tumors – by removing the local environment’s strong immunosuppression signals by a variety of theoretical mechanisms, to allow the immune system to do its job. I think this general strategy has a good chance of working – the only unknown is which specific trick (or combination of tricks) will do the job…
-DK